Stimulants-related bruxism has been previously reported; both diurnal and nocturnal. Here, authors report on a case of methylphenidate (MPH)-treated attention-deficit/hyperactivity disorder that developed nocturnal bruxism and failed multiple pharmacologic trials. Add-on clonidine has successfully helped with bruxisms while augmenting MPH response. This was achieved with great tolerability. This remains a viable option to deploy in such unusual clinical scenarios.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association, 2013.
2.
ChenWH, LuYC, LuiCC, LiuJS: A proposed mechanism for diurnal/nocturnal bruxism: Hypersensitivity of presynaptic dopamine receptors in the frontal lobe. J Clin Neurosci, 12:161–163, 2005.
3.
GuaitaM, HoglB: Current treatments of bruxism. Curr Treat Opinions Neurol, 18:10, 2016.
4.
MendhekarDN, AndradeC: Bruxism arising during monotherapy with methylphenidate. J Child Adolesc Psychopharmacol, 18:537–538, 2008.
5.
NaguyA: Clonidine use in psychiatry: Panacea or panache?. Pharmacology, 98:87–92, 2016.
6.
SabuncuogluO, EkinciO, BerkemM: Fluoxetine-induced sleep bruxism in an adolescent treated with buspirone: A case report. Spec Care Dentist, 29:215–217, 2009.
7.
SakaiT, KatoT, YoshizawaS, SuganumaT, TakabaM, OnoY, YoshizawaA, YoshidaY, KuriharaT, IshiiM, KawanaF, KiuchiY, BabaK: Effect of clonazepam and clonidine on primary sleep bruxism: A double-blind, cross-over, placebo-controlled trial. J Sleep Res, 26:73–83, 2017.
8.
YuceM, KarabekirogluK, SayGN, MujdeciM, OranM: Buspirone use in the treatment of atomoxetine-induced bruxism. J Child Adolesc Psychopharmacol, 23:634–635, 2013.
